Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation— the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study
Paolo Verdecchia(Azienda Ospedaliera di Perugia), Giuseppe Di Pasquale, Eva Kleine(Boehringer Ingelheim (Germany)), Gregory Y.H. Lip(Medical University of Białystok), Lars Wallentin(Uppsala University), Gianpaolo Reboldi(Ca' Foncello Hospital), Stuart J. Connolly(Population Health Research Institute), Fabio Angeli(University of Insubria), Martina Brueckmann(Boehringer Ingelheim (Germany)), Salim Yusuf(Population Health Research Institute), Giovanni Mazzotta(University of Perugia), Michael D. Ezekowitz(Lankenau Institute for Medical Research)
Cited by 19
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
|Stroke|2014|5.2k
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
|European Heart Journal|2017|3k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k